← Patent-cliff monitor small molecule SOHONOS PALOVAROTENE
Loss of exclusivity June 2037 latest FDA-listed patent expiry
Company IPSEN BIOPHARMACEUTICALS INC
Drug detail Brand name SOHONOS Active ingredient PALOVAROTENE Strength 1MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval August 2023 Marketing status RX
Listed patents Patent Expires Type 11622959 June 2037 use U-3676 10864194 June 2037 use U-3676 12458626 June 2037 use U-3676 12138245 June 2037 use U-4031 12201614 June 2037 use U-4031 12023312 August 2031 use U-3966 10292954 August 2031 use U-3676 9789074 August 2031 use U-3676 9314439 August 2031 use U-3676
Regulatory exclusivity Code Expires ODE-439 August 2030 NCE August 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.